Neoplasm of uncertain behavior of other and unspecified sites and tissues
Neoplasm of uncertain behavior of bone and articular cartilage
Neoplasm of uncertain behavior of connective and other soft tissue
Neoplasm of uncertain behavior of skin
Neoplasm of uncertain behavior of breast
Polycythemia vera
- myeloproliferative disorder characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume; associated frequently with splenomegaly, leukocytosis, and thrombocythemia.
- A chronic myeloproliferative disorder characterized by an increased red blood cell production. Excessive proliferation of the myeloid lineage is observed as well. The major symptoms are related to hypertension or to vascular abnormalities caused by the increased red cell mass. The cause is unknown. With currently available treatment, the median survival exceeds 10 years. (WHO, 2001)
Neoplasm of uncertain behavior of histiocytic and mast cells
- A nodule of mast cells. Mastocytomas can involve the skin, subcutaneous tissue, and sometimes muscle. Also called a mast cell tumor.
- A localized tumor composed of sheets of mast cells without atypia. It includes the cutaneous mastocytoma which involves the dermis and subcutaneous tissue, and the extracutaneous mastocytoma. Most cases of extracutaneous mastocytoma have been reported in the lung.
- nodular cutaneous mast cell infiltrate, which is usually present at birth or soon after as a solitary nodule, although three to four lesions may occur; lesions typical of urticaria pigmentosa may occur later.
- A heterogeneous group of disorders characterized by the abnormal growth and accumulation of mast cells in one or more organ systems. Recent data suggest that most variants of mastocytosis are clonal disorders. (WHO, 2001) -- 2003
Neoplasm of uncertain behavior of plasma cells
- (PLAS-ma-sye-TOE-ma) Cancer of the plasma cells (white blood cells that produce antibodies) that may turn into multiple myeloma.
- A malignant (clonal) proliferation of plasma cells that are cytologically and immunophenotypically identical to those of plasma cell myeloma, but manifest a localized osseous or extraosseous growth pattern. (WHO, 2001)
- A single focus of clonal (malignant) plasma cells either in the bone or in another anatomic site without peripheral blood involvement. --2003
Neoplasm of uncertain behavior of other lymphatic and hematopoietic tissues
- An acute myeloid leukemia characterized by bone marrow fibrosis. The prognosis is usually poor. (WHO, 2001)
- Chronic myeloproliferative disorders (CMPDs) are clonal hematopoietic stem cell disorders, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, and megakaryocytic) lineages. The proliferation is associated with relatively normal, effective maturation, resulting in increased numbers of granulocytes, red blood cells, and/or platelets in the peripheral blood. CMPDs are primarily diseases of adults.
Essential thrombocythemia
- clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets.
- An increased number of thrombocytes (platelets) in the blood, without a known cause.
- A chronic myeloproliferative disorder that involves primarily the megakaryocytic lineage. It is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage. The cause is unknown. Median survival times of 10-15 years are commonly reported. (WHO, 2001)
Low grade myelodysplastic syndrome lesions
- A myelodysplastic syndrome characterized mainly by dysplasia of the erythroid series. Refractory anemia is uncommon. It is primarily a disease of older adults. The median survival exceeds 5 years. (WHO, 2001)
- A myelodysplastic syndrome characterized by an anemia in which 15% or more of the erythroid precursors are ringed sideroblasts. The ring sideroblast is an erythroid precursor in which one third or more of the nucleus is encircled by granules which are positive for iron stain. It occurs primarily in older individuals. The median survival exceeds 5 years. (WHO, 2001)
High grade myelodysplastic syndrome lesions
Myelodysplastic syndrome with 5q deletion
Myelodysplastic syndrome, unspecified
- Abnormal bone marrow cells that may lead to myelogenous leukemia.
- (MYE-eh-lo-dis-PLAS-tik SIN-drome) Disease in which the bone marrow does not function normally.
- A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)
Myelofibrosis with myeloid metaplasia
- A disorder in which the bone marrow is replaced by fibrous tissue.
- A progressive disease in which the bone marrow is replaced by fibrous tissue and is unable to produce red blood cells; the cause is unknown.
- A chronic myeloproliferative disorder characterized by bone marrow fibrosis, proliferation of atypical megakaryocytes and granulocytes in the bone marrow, anemia, splenomegaly, and extramedullary hematopoiesis. The cause is unknown. The median survival time is 3-5 years from diagnosis. (WHO, 2001)
Post-transplant lymphoproliferative disorder (ptld)
- Post-transplant lymphoproliferative disorder (PTLD) is a polyclonal (benign) or clonal (malignant) proliferation of lymphoid cells that develops as a consequence of immunosuppression in a recipient of a solid organ or bone marrow allograft. PTLDs comprise a spectrum ranging from early, Epstein-Barr virus (EBV)-driven polyclonal lymphoid proliferations to EBV-positive or EBV- negative lymphomas of predominantly B-cell or less often T-cell type. (WHO, 2001) -- 2003
Other lymphatic and hematopoietic tissues
- An acute myeloid leukemia characterized by bone marrow fibrosis. The prognosis is usually poor. (WHO, 2001)
- Chronic myeloproliferative disorders (CMPDs) are clonal hematopoietic stem cell disorders, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, and megakaryocytic) lineages. The proliferation is associated with relatively normal, effective maturation, resulting in increased numbers of granulocytes, red blood cells, and/or platelets in the peripheral blood. CMPDs are primarily diseases of adults.
Neoplasm of uncertain behavior of other specified sites
Neoplasm of uncertain behavior site unspecified
